Two new research papers have been published that highlight how our prescription data is driving insights into adrenaline auto-injector provision and dosing to improve patient outcomes.
The first study, conducted in collaboration with Gateshead Health NHS Foundation Trust and Newcastle Upon Tyne Hospitals NHS Foundation Trust, investigated anaphylaxis treatment in community settings. The research focused on adrenaline auto-injector (AAI) devices, which deliver life-saving intramuscular adrenaline injections during severe allergic reactions.
Analysis of community AAI prescriptions revealed that non-standard AAI prescribing in both children and adults is not uncommon across England. This insight provides crucial evidence for healthcare providers and policymakers working to improve anaphylaxis management and patient safety.
Adrenaline Auto-Injector Prescribing in Primary Care in England: An Analysis of Non-Standard Dosing
The second research paper examined the economics of emergency AAI provision in schools. Using our prescription data, researchers estimated the costs of two different approaches:
- providing patient-specific prescribing to remain on school premises
- supplying schools with "spare" AAIs that can be used for any pupil experiencing anaphylaxis
These cost-effectiveness findings will support Integrated Care Boards (ICBs) and healthcare decision makers in developing policies that improve emergency access to AAIs, ultimately enhancing safety for children with severe allergies in school.
Both studies demonstrate how our comprehensive prescription data can generate actionable insights through advanced analytics and data science. By collaborating with NHS trusts and external research partners, we're transforming raw data into evidence that informs healthcare policy and improves patient outcomes.
The research papers were published by The Clinical and Experimental Allergy and The Archive of Disease in Childhood Journals.